Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

NCT05754710 · tracked via the Priya Life Science South Korea tracker

Sponsor

Pfizer

Phase

Observational

Started

2024-04-12

Last updated

2026-08-03

Condition(s) studied

Psoriatic Arthritis, JuvenilePolyarticular Juvenile Idiopathic Arthritis

Investigational drug(s) / intervention(s)

Xeljanz →

Xeljanz: Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz

Study summary

This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study.

Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea.

This study is seeking patients who:

* Are 2 to less than 18 years of age;
* Are given Xeljanz for the treatment of JIA.

The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.

Eligibility

Sex

ALL

Min age

2 Years

Max age

17 Years

Healthy volunteers

Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Pediatric subjects aged from 2 years to less than 18 years 2. Xeljanz administered according to efficacy/effectiveness on the approved labeling 3. Patients who will administer Xeljanz based on the medical judgement of the investigator 4. Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: Subjects meeting any of the following criteria will not be included in the study: 1\) Subjects who are contraindicated from taking Xeljanz according to approved labeling\* \*Refer to most recently approved label

Primary outcome measure(s)

Number of patients with treatment emergent treatment-related adverse events — Maximum of 12 months from the time of first administration of Xeljanz
Incidence of each adverse event (AE) will be presented with 95% confidence interval. Serious, related, and/or unexpected AEs will be summarized separately. Additionally, in the event that AEs designated as important potential risks and important identified risks are reported, or if a patient in the missing information group is recruited, related safety information will be provided separately.

Trial sites (1)

Facility	City	Region	Status
Pfizer	Seoul	South Korea	Recruiting

More Pfizer trials in South Korea

Korea Comirnaty Post-marketing Surveillance Active, not recruiting

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market Recruiting

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Active, not recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors Recruiting

Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05754710 on ClinicalTrials.gov ↗ ← All trials in South Korea